RT Journal Article
SR Electronic
A1 Jacobson, Anne
T1 Candesartan Reverses Retinopathy in Type 2 Diabetes
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 7
SP 15
OP 16
DO 10.1177/155989770800800707
UL http://mdc.sagepub.com/content/8/7/15.abstract
AB Candesartan may have a place in the treatment of retinopathy in patients with type 1 or 2 diabetes, according to findings from the Diabetic Retinopathy Candesartan Trials (DIRECT) study program. The DIRECT-Protect 1 and 2 trials are the first to show the potential benefits of angiotensin-II receptor blockers in patients with baseline diabetic retinopathy.